Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.Dynatrace initiated with a Buy at Goldman Sachs Goldman Sachs analyst Kash Rangan initiated coverage of Dynatrace with a Buy rating and $65 price target. Dynatrace is a "unique" software infrastructure provider in that the company's technology stack is deployed by customers for application monitoring and in production environments as well as in front office business use cases and in development environments, Rangan tells investors in a research note. The analyst believes the company has built a "durable and balanced" business model which has the ability to generate subscription revenue growth at 30%-plus over the long term.Our Take: "A nice tech holding in the currently much needed 'work from home' space. Buying dips and selling peaks here." $DT, Dynatrace, Inc. / H1 Horizon Therapeutics resumed with an Overweight at Morgan StanleyMorgan Stanley analyst David Risinger resumed coverage of Horizon Therapeutics with an Overweight rating and $103 price target following the completion of the company's "potentially transformational" acquisition of Viela Bio. The firm's survey work on top drug Tepezza highlights opportunities for growth, he sees strong growth potential for Viela's Uplizna and believes Viela's pipeline could offer "even greater value-creation potential," Risinger tells investors.Our Take: "HZNP just keeps performing, this was a major winner last year and the momentum continues."Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)! Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .